A novel diagnostic serum protein signature for pediatric inflammatory bowel disease
Journal of Pediatric Gastroenterology and Nutrition, 2026
Mathisen C., Nyström N., Bazov I., Øyås O., Zucknick M., Andersen S., Olbjørn C., Perminow G., Kristensen V., Opheim R., D'Amato M., Carlson M., Hedin C., Keita ?., Lindqvist C., Magnusson M., Salihovic S., Söderholm J., Öhman L., Kruse R., Repsilber D., Halfvarson J., Høivik M.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
Immunological & Inflammatory Diseases | Patient Stratification | Serum |  Olink Target 96 |
Abstract
Objectives
Diagnostic delay is common in pediatric inflammatory bowel disease (PIBD), and fecal calprotectin (FCP) is often limited by challenges with sample collection. Therefore, we aimed to identify and validate a blood‐based diagnostic protein signature of PIBD.
Methods
Proteins were analyzed using proximity extension assay in plasma samples from treatment‐naïve pediatric patients in a Swedish inception cohort referred for suspected IBD and validated in an independent Norwegian population‐based pediatric inception cohort. Diagnostic performance was estimated by the area under the curve (AUC) with 95% confidence intervals (CIs).
Results
The discovery cohort included 58 patients with PIBD and 36 symptomatic controls without evidence of IBD, while the validation cohort consisted of 79 patients with PIBD and 37 symptomatic controls. In total, 154 proteins were examined. Univariable analyses identified 26 differentially regulated proteins for PIBD versus symptomatic controls in the discovery cohort ( q < 0.05), whereas 29 proteins were differentially regulated in the validation cohort. Using regularized logistic regression, we identified a diagnostic model of 31 proteins that differentiated PIBD from symptomatic controls in the discovery cohort (AUC = 0.83; 95% CI: 0.74–0.90). The protein signature was further reduced to a clinically relevant biomarker consisting of high‐sensitivity C‐reactive protein (hsCRP) and seven other proteins with diagnostic capacity (AUC = 0.85, 95% CI: 0.78–0.92) outperforming hsCRP in the validation cohort ( p = 0.006).
Conclusions
We identified and validated a blood‐based protein signature for PIBD with superior diagnostic performance compared to hsCRP. Given the challenges of fecal sample collection, further assay development may enable integration of these biomarkers into diagnostic pathways for PIBD.
Trial Registration
ClinicalTrials.gov identifier: NCT02727959.